Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Addex Therapeutics (ADXN) Invested Capital (2018 - 2025)

Addex Therapeutics' Invested Capital history spans 8 years, with the latest figure at $6.0 million for Q4 2025.

  • On a quarterly basis, Invested Capital fell 46.01% to $6.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.0 million, a 46.01% decrease, with the full-year FY2025 number at $5.7 million, down 47.96% from a year prior.
  • Invested Capital came in at $6.0 million for Q4 2025, down from $11.0 million in the prior quarter.
  • The five-year high for Invested Capital was $18.4 million in Q4 2021, with the low at $1.3 million in Q4 2023.
  • Historically, Invested Capital has averaged $8.4 million across 5 years, with a median of $6.0 million in 2025.
  • Biggest five-year swings in Invested Capital: tumbled 74.68% in 2023 and later soared 755.45% in 2024.
  • Year by year, Invested Capital stood at $18.4 million in 2021, then plummeted by 72.23% to $5.1 million in 2022, then plummeted by 74.68% to $1.3 million in 2023, then surged by 755.45% to $11.0 million in 2024, then tumbled by 46.01% to $6.0 million in 2025.
  • Business Quant data shows Invested Capital for ADXN at $6.0 million in Q4 2025, $11.0 million in Q4 2024, and $1.3 million in Q4 2023.